Cytosorbents Statistics
Total Valuation
Cytosorbents has a market cap or net worth of $12.95 million. The enterprise value is $37.96 million.
| Market Cap | 12.95M |
| Enterprise Value | 37.96M |
Important Dates
The next estimated earnings date is Thursday, November 12, 2026, after market close.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cytosorbents has 3.15 million shares outstanding. The number of shares has increased by 8.00% in one year.
| Current Share Class | 3.15M |
| Shares Outstanding | 3.15M |
| Shares Change (YoY) | +8.00% |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | 11.78% |
| Owned by Institutions (%) | 25.59% |
| Float | 2.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.35 |
| Forward PS | 0.30 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.02 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.66
| Current Ratio | 0.66 |
| Quick Ratio | 0.47 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.78 |
Financial Efficiency
Return on equity (ROE) is -336.21% and return on invested capital (ROIC) is -21.86%.
| Return on Equity (ROE) | -336.21% |
| Return on Assets (ROA) | -17.12% |
| Return on Invested Capital (ROIC) | -21.86% |
| Return on Capital Employed (ROCE) | -84.46% |
| Weighted Average Cost of Capital (WACC) | 9.41% |
| Revenue Per Employee | $288,496 |
| Profits Per Employee | -$141,194 |
| Employee Count | 129 |
| Asset Turnover | 0.87 |
| Inventory Turnover | 2.86 |
Taxes
| Income Tax | -401,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -77.57% in the last 52 weeks. The beta is 1.37, so Cytosorbents's price volatility has been higher than the market average.
| Beta (5Y) | 1.37 |
| 52-Week Price Change | -77.57% |
| 50-Day Moving Average | 5.74 |
| 200-Day Moving Average | 9.92 |
| Relative Strength Index (RSI) | 43.88 |
| Average Volume (20 Days) | 42,667 |
Short Selling Information
The latest short interest is 123,890, so 3.93% of the outstanding shares have been sold short.
| Short Interest | 123,890 |
| Short Previous Month | 120,606 |
| Short % of Shares Out | 3.93% |
| Short % of Float | 4.46% |
| Short Ratio (days to cover) | 4.71 |
Income Statement
In the last 12 months, Cytosorbents had revenue of $37.22 million and -$18.21 million in losses. Loss per share was -$5.82.
| Revenue | 37.22M |
| Gross Profit | 26.65M |
| Operating Income | -11.77M |
| Pretax Income | -18.62M |
| Net Income | -18.21M |
| EBITDA | -10.35M |
| EBIT | -11.77M |
| Loss Per Share | -$5.82 |
Balance Sheet
The company has $4.41 million in cash and $29.43 million in debt, with a net cash position of -$25.01 million or -$7.94 per share.
| Cash & Cash Equivalents | 4.41M |
| Total Debt | 29.43M |
| Net Cash | -25.01M |
| Net Cash Per Share | -$7.94 |
| Equity (Book Value) | -751,000 |
| Book Value Per Share | -0.24 |
| Working Capital | -8.29M |
Cash Flow
In the last 12 months, operating cash flow was -$9.15 million and capital expenditures -$150,000, giving a free cash flow of -$9.30 million.
| Operating Cash Flow | -9.15M |
| Capital Expenditures | -150,000 |
| Depreciation & Amortization | 1.42M |
| Net Borrowing | 2.48M |
| Free Cash Flow | -9.30M |
| FCF Per Share | -$2.95 |
Margins
Gross margin is 71.61%, with operating and profit margins of -31.63% and -48.94%.
| Gross Margin | 71.61% |
| Operating Margin | -31.63% |
| Pretax Margin | -50.02% |
| Profit Margin | -48.94% |
| EBITDA Margin | -27.81% |
| EBIT Margin | -31.63% |
| FCF Margin | n/a |
Dividends & Yields
Cytosorbents does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -8.00% |
| Shareholder Yield | -8.00% |
| Earnings Yield | -140.64% |
| FCF Yield | -71.79% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 11.66% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 8, 2026. It was a reverse split with a ratio of 1:20.
| Last Split Date | Sep 8, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Cytosorbents has an Altman Z-Score of -11.45 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.45 |
| Piotroski F-Score | 4 |